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KEY POINTS

Interplay between myeloma niche stromal cells and myeloid cells
generates versikine, a novel damage-associated-molecular pattern (DAMP).
2. Versikine may promote antigen-presenting cell maturation and CD8+ T cell activation/recruitment to the tumor bed.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From ABSTRACT Myeloma immunosurveillance remains incompletely understood. We have demonstrated proteolytic processing of the matrix proteoglycan, versican, in myeloma tumors. Whereas intact versican exerts tolerogenic activities through Toll-like receptor (TLR)-2 binding, the immunoregulatory consequences of versican proteolysis remain unknown. Here we show that human myeloma tumors displaying CD8+ infiltration/aggregates underwent versican proteolysis at a site predicted to generate a glycosaminoglycan-bereft N-terminal fragment, versikine. Myeloma-associated macrophages (MAM), but not tumor cells, produced V1-versican, the precursor to versikine, whereas stromal cell-derived ADAMTS1 was the most robustly expressed versican-degrading protease.
Purified versikine induced early expression of inflammatory cytokines IL1β and IL6 by human myeloma marrow-derived MAM. We show that versikine signals through pathways both dependent and independent of Tpl2 kinase, a key regulator of NFκB1-mediated MAPK activation in macrophages. Unlike intact versican, versikine-induced IL6 production was partially independent of Tlr2. In a model of macrophage-myeloma cell crosstalk, versikine induced components of "T-cell-inflammation", including IRF8-dependent type I-interferon (IFN)transcriptional signatures and T-cell-chemoattractant CCL2. Thus the interplay between stromal cells and myeloid cells in the myeloma microenvironment generates versikine, a novel bioactive damage-associated-molecular-pattern (DAMP) that may facilitate immune sensing of myeloma tumors and modulate the 
INTRODUCTION
Myeloma is a tumor of plasma cells which are antibody-producing, terminally differentiated B lymphocytes 1 . Myeloma plasma cells typically live within the bone marrow microenvironment ("canonical" myeloma niche) but can often thrive in extramedullary sites and soft tissues ("non-canonical" niches).
We have hypothesized that infiltrating myeloid cells may exert crucial trophic and immunoregulatory functions in both "canonical" and "non-canonical" niches, in part through their regulation of extracellular matrix composition and remodeling 2 .
We and others have previously demonstrated that versican, a large, chondroitinsulfate matrix proteoglycan, accumulates in myeloma lesions and have hypothesized that versican may contribute to myeloma niche immunoregulation 3, 4 . Versican has crucial, non-redundant significance in embryonic development 5 and emerging roles in cancer inflammation and metastasis [6] [7] [8] [9] . Versican promotes tolerogenic polarization of antigen-presenting cells through TLR2 10 . Versican is proteolytically cleaved by ADAMTS-type proteases in a highly-regulated manner 5 . A cleavage product generated by proteolysis of the Glu 441 -Ala 442 bond within the versican V1 isoform, has been termed versikine 5 . Versikine has been shown to be bioactive (proapoptotic) during interdigital web regression in the mouse embryo 11 ; however, the roles of versican proteolysis and/or versikine in tumor immunomodulation remain unknown.
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METHODS.
Versikine production, purification and analysis. Methods for expression and purification of recombinant versikine from mammalian cells have been published 12, 13 . We excluded endotoxin and hyaluronan contamination as detailed in 
RESULTS AND DISCUSSION
To determine whether versikine acts as an endogenous DAMP, we exposed freshly-explanted primary myeloma CD14+ cells to recombinant human versikine (1μM). Versikine rapidly induced inflammatory cytokines IL1β and IL6 ( Figure   1A Versican, the precursor to versikine, has been variably reported to be expressed by carcinoma tumor cells or components of the carcinoma microenvironment, however its cellular origin in the myeloma niche is unknown. We carried out RT-PCR using versican isoform-specific primers in paired myeloma CD138+ plasma cells, CD14+ monocytes/macrophages and CD14/CD138-double negative fractions from 3 newly-diagnosed patients. All four versican isoforms were predominantly expressed by CD14+ monocytes/macrophages ( Supplementary   Figure 2A ). Known versicanases include ADAMTS-1, -4, -5, -9, -15 and -20 5 . We readily detected ADAMTS1, ADAMTS4 and ADAMTS5 mRNA expression in bone marrow mononuclear cell lysate whereas the rest were undetectable (data not shown). ADAMTS expression has been reported in marrow-derived mesenchymal stromal cells (BM-MSC) 14 . We found that ADAMTS1 was expressed at higher levels by myeloma-derived BM-MSC compared to normal donor BM-MSC (Supplementary Figure 2B ). BM-MSC expressed much higher levels of ADAMTS1 message than either CD138+ plasma cells or CD14+ monocytes/macrophages (Supplementary Figure 2C ). 3, 15 . Tpl2 loss in murine bone-marrow-derived macrophages (BMDM) abrogated IL1β production in response to versikine but had little impact on IL6 production ( Figure 1C ). Interestingly, versikine induced IL12p40 but not IL10
( Figure 1D and 1E ). Tpl2 negatively regulated IL12p40 production in response to versikine ( Figure 1D ), in a manner analogous to TLR agonists 16 . Whereas versikine induced IL12p40 in isolation, concurrent Fcγ receptor ligation through addition of ovalbumin (OVA)/anti-OVA immune complexes promoted IL10 production and skewed macrophage polarization towards an immunoregulatory M2b phenotype (IL12 lo -IL10 hi ) 17 ( Figure 1E ).
Intact versican is thought to signal through TLR2 10 . However, Tlr2-/-BMDM showed only a partial IL6 production defect (approximately 50%) in response to recombinant versikine ( Figure 1F ).
Versikine stimulation of wild-type BMDM rapidly induced JNK, p38-MAPK and AKT phosphorylation but Tpl2 loss only affected p38-MAPK phosphorylation ( Figure 1G ).
Human THP-1 monocytic cells can be induced to generate macrophages that provide a functional model to study macrophage regulation, including polarization 18 . THP-1 macrophages transduced with versikine-plasmid or empty-vector control, were co-cultured with human myeloma MM1.S cells for 48 hours and RNA-seq analysis was performed on each cell type. Remarkably, only 23 genes were differentially expressed in MM1.S cells exposed to versikine-secreting Figure 2C ). Irf8 expression in transplanted tumor cells has been shown to be inducible through an Il27-dependent mechanism 19 . We observed upregulation of the IL27 subunit,
EBI3, in tumor cells and in primary MAM treated with versikine (Figures 2D and 2E).
We stained myeloma bone marrow biopsy sections with antibodies against a versican neoepitope (DPEAAE 441 ) generated by Glu 441 -Ala 442 cleavage of V1versican 5 . DPEAAE 441 constitutes the C-terminus of versikine. Consecutive sections were stained for T cell marker CD8. We observed four staining patterns in 19 core biopsies ( Figure 2F ). Myeloma tumors displaying CD8+ We hypothesized that the regulated degradation of versican by ADAMTS-type versicanases may modulate its tolerogenic potential by controlling versican bioavailability, disrupting its extracellular matrix networks and/or by generating novel bioactive fragments. We report that versikine, a product of versican proteolysis, possesses immunoregulatory activities that may promote innate myeloma sensing and "T-cell-inflammation" through induction of type-I-IFN signatures, macrophage activation (IL1β, IL6), T-cell chemotactic mediators (CCL2) 21, 22 and IRF8 activation, the latter known to be critical for dendritic and myeloid-derived suppressor cell maturation and homeostasis, respectively 23, 24 as well as macrophage inflammatory responses 25 (Figure 2G ). Taken together, our results suggest that versikine may antagonize the tolerogenic actions of intact versican and thus, may provide a novel anti-tumor strategy. The findings also suggest that, in addition to small leucine-rich proteoglycans, previously shown to act as DAMPs 26 , fragments of large aggregating proteoglycans may have the capacity to stimulate innate immunity and provide a bridge to adaptive immunity. 
